Nektar Therapeutics NKTR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's accrued expenses?
- Nektar Therapeutics (NKTR) reported accrued expenses of $5.01M in Q1 2026.
- How has Nektar Therapeutics's accrued expenses changed year-over-year?
- Nektar Therapeutics's accrued expenses decreased by 0.4% year-over-year, from $5.03M to $5.01M.
- What is the long-term trend for Nektar Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Nektar Therapeutics's accrued expenses has grown at a -27.4% compound annual growth rate (CAGR), from $14.53M to $2.94M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.